Rasmussen S, Leth A, Ibsen H, Damkjaer Nielsen M, Nielsen F, Giese J
Acta Med Scand. 1986;219(1):29-36. doi: 10.1111/j.0954-6820.1986.tb03272.x.
In 24 patients with mild/moderate essential hypertension, we studied the effects of captopril with/without hydrochlorothiazide (Htz) on blood pressure, the renin-angiotensin system, blood bradykinin concentration (BBK), plasma volume, exchangeable sodium and glomerular filtration. Daily captopril doses of 75 and 150 mg were equally effective in reducing the blood pressure. Addition of Htz caused further blood pressure reductions. Nineteen patients attained a diastolic blood pressure less than or equal to 90 mmHg. Angiotensin converting enzyme inhibition with captopril led to a fall in plasma concentrations of angiotensin II (PAII) and renin substrate, and an increase in plasma concentrations of renin and angiotensin I. Patients starting with Htz had a higher PAII and subsequently a larger fall in blood pressure on captopril than untreated patients. BBK remained unchanged, indicating that the hypotensive action of captopril does not involve an accumulation of circulating kinin. Body fluid volumes and renal function were not affected by the various treatment regimens.
在24例轻度/中度原发性高血压患者中，我们研究了卡托普利单用或联用氢氯噻嗪（Htz）对血压、肾素-血管紧张素系统、血缓激肽浓度（BBK）、血浆容量、可交换钠及肾小球滤过的影响。每日75毫克和150毫克剂量的卡托普利在降低血压方面效果相同。加用Htz可进一步降低血压。19例患者舒张压降至90毫米汞柱或更低。卡托普利抑制血管紧张素转换酶导致血浆血管紧张素II（PAII）和肾素底物浓度下降，肾素和血管紧张素I血浆浓度升高。起始就使用Htz的患者与未治疗患者相比，PAII更高，随后使用卡托普利时血压下降幅度更大。BBK保持不变，表明卡托普利的降压作用不涉及循环激肽的蓄积。不同治疗方案对体液容量和肾功能无影响。
